TaiMed Biologics Inc (中裕新藥), an HIV/AIDS drug developer, yesterday denied that it is eyeing profits from an anticipated spike in the spread of the disease following the Council of Grand Justices’ ruling that paved the way for the legalization of same-sex marriage.
The rumors are malicious and have damaged the company’s reputation, it said in a filing with the Taiwan Stock Exchange.
The company said that research on its HIV/AIDS drug TMB-355 began more than a decade ago and it placed a lower priority on commercializing the drug in the Taiwan market since listing on the Taipei Exchange in November 2015.
“Due to stringent controls imposed on drug prices under the National Health Insurance scheme, we have ruled out expectations of significant profit in the domestic market,” the company said, adding that its focus is on overseas markets.
The company said that the US market for AIDS/HIV treatments is about 100 times larger than the local market and it has submitted a new drug application to US health authorities.
None of its major stakeholders have strong political leanings, TaiMed said, adding that it has not been in contact with political figures, interest groups or institutions.
Same-sex marriage is a social issue rather than an economic or business matter, it said.
While employees are free to voice their opinions on the matter, TaiMed does not have a stance, it said.
The company urged the government to develop legislation to mitigate social discord.
Meanwhile, TaiMed president and chief executive officer James Chang (張念原) said at a shareholders’ meeting on Friday last week that the company hopes TMB-355 would contribute to sales before the end of the year.
The company has invested more than US$30 million to prepare for TMB-355’s launch in the US, and it has hired 25 salespeople and secured four distribution partnerships there, Chang said.
A protein-drug manufacturing plant in Hsinchu is to break ground this month and is expected to help reduce production costs by the second half of next year, he said.
Investors have been battered by a recent bubble in the local biotechnology sector, he said, adding that the firm’s shares have been undervalued.
TaiMed shares yesterday gained 5.85 percent to close at NT$190, outpacing the Taipei Exchange’s 0.04 percent rise.
ISSUES: Gogoro has been struggling with ballooning losses and was recently embroiled in alleged subsidy fraud, using Chinese-made components instead of locally made parts Gogoro Inc (睿能創意), the nation’s biggest electric scooter maker, yesterday said that its chairman and CEO Horace Luke (陸學森) has resigned amid chronic losses and probes into the company’s alleged involvement in subsidy fraud. The board of directors nominated Reuntex Group (潤泰集團) general counsel Tamon Tseng (曾夢達) as the company’s new chairman, Gogoro said in a statement. Ruentex is Gogoro’s biggest stakeholder. Gogoro Taiwan general manager Henry Chiang (姜家煒) is to serve as acting CEO during the interim period, the statement said. Luke’s departure came as a bombshell yesterday. As a company founder, he has played a key role in pushing for the
China has claimed a breakthrough in developing homegrown chipmaking equipment, an important step in overcoming US sanctions designed to thwart Beijing’s semiconductor goals. State-linked organizations are advised to use a new laser-based immersion lithography machine with a resolution of 65 nanometers or better, the Chinese Ministry of Industry and Information Technology (MIIT) said in an announcement this month. Although the note does not specify the supplier, the spec marks a significant step up from the previous most advanced indigenous equipment — developed by Shanghai Micro Electronics Equipment Group Co (SMEE, 上海微電子) — which stood at about 90 nanometers. MIIT’s claimed advances last
CROSS-STRAIT TENSIONS: The US company could switch orders from TSMC to alternative suppliers, but that would lower chip quality, CEO Jensen Huang said Nvidia Corp CEO Jensen Huang (黃仁勳), whose products have become the hottest commodity in the technology world, on Wednesday said that the scramble for a limited amount of supply has frustrated some customers and raised tensions. “The demand on it is so great, and everyone wants to be first and everyone wants to be most,” he told the audience at a Goldman Sachs Group Inc technology conference in San Francisco. “We probably have more emotional customers today. Deservedly so. It’s tense. We’re trying to do the best we can.” Huang’s company is experiencing strong demand for its latest generation of chips, called
EUROPE ON HOLD: Among a flurry of announcements, Intel said it would postpone new factories in Germany and Poland, but remains committed to its US expansion Intel Corp chief executive officer Pat Gelsinger has landed Amazon.com Inc’s Amazon Web Services (AWS) as a customer for the company’s manufacturing business, potentially bringing work to new plants under construction in the US and boosting his efforts to turn around the embattled chipmaker. Intel and AWS are to coinvest in a custom semiconductor for artificial intelligence computing — what is known as a fabric chip — in a “multiyear, multibillion-dollar framework,” Intel said in a statement on Monday. The work would rely on Intel’s 18A process, an advanced chipmaking technology. Intel shares rose more than 8 percent in late trading after the